Home/Filings/4/0001161697-26-000022
4//SEC Filing

Kalb Michael Wayne 4

Accession 0001161697-26-000022

CIK 0001369568other

Filed

Jan 5, 7:00 PM ET

Accepted

Jan 6, 5:00 PM ET

Size

9.3 KB

Accession

0001161697-26-000022

Insider Transaction Report

Form 4
Period: 2026-01-05
Kalb Michael Wayne
Executive Vice President & CFO
Transactions
  • Exercise/Conversion

    Common Stock, par value $0.001 per share

    2026-01-05+7,13915,745 total
  • Tax Payment

    Common Stock, par value $0.001 per share

    2026-01-052,08013,665 total
  • Exercise/Conversion

    Restricted Stock Units

    2026-01-057,139632,903 total
    Common Stock (7,139 underlying)
Footnotes (4)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
  • [F2]Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
  • [F3]Derivative securities vest in equal tranches, 1/5th on January 1, 2025, 1/5th on January 1, 2026, 1/5th on January 1, 2027, 1/5th on January 1, 2028, and 1/5th on January 1, 2029.
  • [F4]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on January 5, 2026.

Issuer

CATALYST PHARMACEUTICALS, INC.

CIK 0001369568

Entity typeother

Related Parties

1
  • filerCIK 0001678248

Filing Metadata

Form type
4
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 5:00 PM ET
Size
9.3 KB